The increased incidence of heart disease in the developed world has led to the continuous expansion of the cardiovascular disease market. Predominantly, the market for statins, drugs that lower LDL cholesterol levels through the inhibition of HMG CoA reductase was top with increasing annual growth. This feature focuses on statins and various strategies adopted by the Pharma players to exploit the maturing statin market.